156 related articles for article (PubMed ID: 20533074)
1. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines.
Budman DR; Tai J; Calabro A; John V
Invest New Drugs; 2011 Dec; 29(6):1224-9. PubMed ID: 20533074
[TBL] [Abstract][Full Text] [Related]
2. Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Budman DR; Calabro A; Rosen L; Lesser M
Anticancer Drugs; 2012 Mar; 23(3):272-9. PubMed ID: 23427335
[TBL] [Abstract][Full Text] [Related]
3. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
4. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of docetaxel in epithelial ovarian cancer via PI3K/Akt pathway in vitro.
Chao H; Wang L; Hao J; Ni J; Chang L; Graham PH; Kearsley JH; Li Y
Cancer Lett; 2013 Feb; 329(1):17-26. PubMed ID: 22995071
[TBL] [Abstract][Full Text] [Related]
5. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
6. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
7. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
8. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.
Wang G; Edwards H; Caldwell JT; Buck SA; Qing WY; Taub JW; Ge Y; Wang Z
PLoS One; 2013; 8(9):e76662. PubMed ID: 24098799
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines.
Angelucci A; Mari M; Millimaggi D; Giusti I; Carta G; Bologna M; Dolo V
Gynecol Oncol; 2010 Dec; 119(3):557-63. PubMed ID: 20825984
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
11. Targeting histone deacetylases (HDACs) and Wee1 for treating high-risk neuroblastoma.
Hanmod SS; Wang G; Edwards H; Buck SA; Ge Y; Taub JW; Wang Z
Pediatr Blood Cancer; 2015 Jan; 62(1):52-9. PubMed ID: 25308916
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Budman DR; Calabro A
Oncology; 2006; 70(2):147-53. PubMed ID: 16645328
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat Synergistically Enhances the Cytotoxicity of Microtubule Destabilizing Drugs in Ovarian Cancer Cells.
Ovejero-Sánchez M; Asensio-Juárez G; González M; Puebla P; Vicente-Manzanares M; Pélaez R; González-Sarmiento R; Herrero AB
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361809
[TBL] [Abstract][Full Text] [Related]
14. The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair.
Maiso P; Colado E; Ocio EM; Garayoa M; Martín J; Atadja P; Pandiella A; San-Miguel JF
Leukemia; 2009 Dec; 23(12):2265-74. PubMed ID: 19812608
[TBL] [Abstract][Full Text] [Related]
15. Pan-HDAC inhibition by panobinostat mediates chemosensitization to carboplatin in non-small cell lung cancer via attenuation of EGFR signaling.
Wang L; Syn NL; Subhash VV; Any Y; Thuya WL; Cheow ESH; Kong L; Yu F; Peethala PC; Wong AL; Laljibhai HJ; Chinnathambi A; Ong PS; Ho PC; Sethi G; Yong WP; Goh BC
Cancer Lett; 2018 Mar; 417():152-160. PubMed ID: 29306016
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.
Wang G; Niu X; Zhang W; Caldwell JT; Edwards H; Chen W; Taub JW; Zhao L; Ge Y
Cancer Lett; 2015 Jan; 356(2 Pt B):656-68. PubMed ID: 25458954
[TBL] [Abstract][Full Text] [Related]
17. Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Wasim L; Chopra M
Biomed Pharmacother; 2016 Dec; 84():1393-1405. PubMed ID: 27802904
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor panobinostat is active in patients with advanced pretreated ovarian sex-cord tumors.
Cassier PA; Floquet A; Penel N; Derbel O; Bui N'guyen B; Guastalla JP; Pissaloux D; Treilleux I; Saba CE; Blay JY; Ray-Coquard I
Ann Oncol; 2014 May; 25(5):1074-5. PubMed ID: 24651409
[No Abstract] [Full Text] [Related]
20. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
